Oniria Therapeutics is pioneering a novel approach to cancer treatment by focusing on the modulation of cell dormancy, a state that allows cancer cells to evade conventional therapies. Their research indicates that dormant cancer cells can persist in the body for extended periods, often leading to treatment resistance and aggressive recurrence. By understanding the vulnerabilities associated with this dormant state, Oniria Therapeutics aims to exploit these weaknesses to develop innovative therapeutic strategies. Their flagship product, ONR-001, is a first-in-class molecule that allosterically activates TET2, an epigenetic enzyme, prompting tumor cells to enter a dormant state or even undergo cell death. This approach is designed to be effective across all stages of cancer, from initial tumors to recurrent metastatic disease.

The company's strategy represents a significant shift in cancer treatment methodology, emphasizing the importance of targeting dormant cancer cells to improve patient outcomes. By translating their findings into advanced treatments, Oniria Therapeutics seeks to prolong patient lives and ultimately achieve cures for previously persistent cancers. Their commitment to addressing the challenges posed by cancer cell dormancy positions them at the forefront of therapeutic innovation in oncology, potentially transforming the landscape of cancer care.

Spain

A shift in cancer treatment methodology makes a world of difference.

Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA).

Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme. 

Oniria Therapeutics

Company Details